KalVista Pharmaceuticals (NASDAQ:KALV) Acquired by Chiesi Group in Strategic Rare Disease Expansion

Font: Financial Modeling Prep  • Apr 30, 2026

• KalVista Pharmaceuticals (NASDAQ:KALV) is being acquired by Chiesi Group for approximately $1.9 billion, a strategic move to expand Chiesi's rare disease treatment portfolio.
• The acquisition offer of $27.00 per share in cash led to a significant 38.62% stock price surge and massive trading volume, reflecting strong investor confidence in the deal's completion.
• Leerink Partners downgraded KalVista Pharmaceuticals' stock to Market Perform with a $27.00 price target, indicating that the stock's value is now primarily tied to the acquisition price.

KalVista Pharmaceuticals is a company that develops treatments for rare diseases. The company is now being acquired by the Italian drugmaker Chiesi Group. This is a strategic move for Chiesi to expand its portfolio of drugs for rare diseases treatment.

As highlighted by Reuters, the pharmaceutical acquisition agreement is for approximately $1.9 billion. Chiesi Group will pay $27.00 per share in cash to purchase KalVista Pharmaceuticals. The news caused the stock price to surge by 38.62%, or $7.43, to close at $26.67. This price is very close to the acquisition offer.

The announcement led to a massive increase in trading activity. The trading volume for the day reached over 69 million shares, a more than 3,300% increase from its three-month average. The stock's closing price near the offer price shows that investor confidence is high that the deal will be completed.

On the same day, April 29, 2026, Leerink Partners downgraded KalVista Pharmaceuticals' stock. The analyst rating was changed to Market Perform from Outperform. A stock downgrade like this often means an analyst believes the stock's future growth is now limited and will likely perform in line with the overall market.

Leerink Partners also set a price target of $27.00 for the stock. This target is identical to the cash price per share offered by Chiesi Group. The new rating and price target reflect that the stock's valuation is now tied directly to the acquisition price, with little room for further increase.